Q2 2026 13F · SEC CIK 1560009
Versant Venture Management, LLC
Venture capitalFiled 2026-08-12 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $162.6M
- Reported positions
- 8
- Top holdings a year, 3 yrs
- -10.3%
- Average holding period
- 1.8 yrs
Versant Venture Management, LLC is a venture capital that reported 8 positions worth $162.6M in its Q2 2026 13F, filed 2026-08-12. Its largest holdings were Monte Rosa Therapeutics Inc (GLUE, 47.3%), Century Therapeutics Inc (IPSC, 18.3%), Jade Biosciences Inc (13.6%). A portfolio copying its top holdings returned -10.3% a year over the last 3 years, against 20.4% for the S&P 500.
Versant Venture Management, LLC holdings all 8 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| GLUEMonte Rosa Therapeutics Inc | 47.3% | +0.0% | $77.0M |
| IPSCCentury Therapeutics Inc | 18.3% | +0.0% | $29.8M |
| 008064206Jade Biosciences Inc | 13.6% | -35.0% | $22.0M |
| LENZLenz Therapeutics Inc | 9.3% | +0.0% | $15.1M |
| CTNMContineum Therapeutics Inc | 5.5% | +0.0% | $8.9M |
| CRSPCRISPR Therapeutics AG | 5.0% | +0.0% | $8.1M |
| SKYESkye Bioscience, Inc. | 0.9% | +0.0% | $1.4M |
| 87978U108Tempest Therapeutics, Inc. | 0.2% | +0.0% | $299K |
What Versant Venture Management, LLC bought and sold in Q2 2026, against Q1 2026.
New positions
No new positions among the largest holdings.
Added to
No position grew by more than 5%.
Reduced
- Jade Biosciences Inc-35.0% shares
Sold out
Nothing sold out.
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- -8.1% /yr
- S&P 500 +20.1%
- 3 years
- -10.3% /yr
- S&P 500 +20.4%
- 5 years
- -26.8% /yr
- S&P 500 +11.6%
A portfolio of the filer's 20 largest 13F positions, weighted by value and rebuilt each quarter on the day the filing became public. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $162.6M | 8 |
| Q1 2026 | $141.4M | 8 |
| Q4 2025 | $151.1M | 7 |
| Q3 2025 | $212.5M | 9 |
| Q2 2025 | $82.1M | 8 |
| Q1 2025 | $60.2M | 7 |
| Q4 2024 | $86.7M | 7 |
| Q3 2024 | $63.6M | 6 |
| Q2 2024 | $77.3M | 8 |
| Q1 2024 | $103.1M | 7 |
| Q4 2023 | $388.8M | 7 |
| Q3 2023 | $188.1M | 8 |
Questions about Versant Venture Management, LLC's portfolio
What stocks does Versant Venture Management, LLC own?
Versant Venture Management, LLC's latest 13F, for Q2 2026 and filed Aug 12, 2026, lists 8 positions worth $162.6M. The largest are Monte Rosa Therapeutics Inc (GLUE) at 47.3%, Century Therapeutics Inc (IPSC) at 18.3%, Jade Biosciences Inc at 13.6%, Lenz Therapeutics Inc (LENZ) at 9.3% and Contineum Therapeutics Inc (CTNM) at 5.5%.
What did Versant Venture Management, LLC buy last quarter?
Versant Venture Management, LLC opened no new positions and grew none by more than 5% among its largest holdings in Q2 2026.
What did Versant Venture Management, LLC sell last quarter?
In Q2 2026, Versant Venture Management, LLC Jade Biosciences Inc (-35.0% shares), compared with its Q1 2026 filing.
How has Versant Venture Management, LLC's portfolio performed?
A portfolio copying Versant Venture Management, LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned -10.3% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: -8.1% against +20.1%. Over 5 years: -26.8% a year against +11.6%.
When is Versant Venture Management, LLC's next 13F filing due?
13F filings are due 45 days after each quarter ends. Versant Venture Management, LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.